ImmunityBio 2 articles

The company-level identity of ImmunityBio is anchored in cancer immunotherapy and N-803 immune cell activation, reflecting a biopharmaceutical company with a defined therapeutic focus. At ImmunityBio, natural killer cell activation sits alongside CD8 T-cell stimulation; bladder cancer immunotherapy adds disease-specific context to the therapeutic profile. GenoMethods uses cytokine-based cancer therapy to help recognize ImmunityBio, without treating any one product or target as the company itself.

Clinical Trials & Evidence

October 8, 2026, 1:26 PM · 4 mins read

Over one hundred firms race to develop new NK cell lymphoma drugs

Clinical trials for natural killer cell lymphoma are ramping up, with more than one hundred companies and over 140 experimental drugs now in play. Novel immunotherapies and combination treatments are reshaping the field.

Clinical Trials & Evidence

October 7, 2026, 10:14 PM · 4 mins read

Experimental CAR-T therapy changes outlook for Utah man with AL amyloidosis

A Utah man with AL amyloidosis saw his prospects shift after joining an experimental CAR-T trial at Huntsman Cancer Institute. His case points to the promise of personalized cell therapies for rare cancers.